The pharmaceutical company Lupin announced on Friday that it had obtained the Establishment Inspection Report (EIR) for its new injectable plant in Nagpur, Maharashtra, from the US Food and Drug Administration. The business stated in a report to the stock exchanges that the EIR was issued following the most recent examination of the facility, which was undertaken from October 17–29, 2022.Generally, USFDA issues an EIR to a firm after an inspection is satisfactorily closed.
“Our cutting-edge injectable facility in Nagpur follows to international norms and is built to the highest quality standards. It also uses cutting-edge technology. We are dedicated to bringing a significant portfolio of injectables from the facility that address unmet requirements, “Lupin’s managing director, Nilesh Gupta, said.
The USFDA granted Lupin approval earlier this month for its Glycopyrrolate Injection USP, a generic version of Hikma Pharmaceuticals USA Inc.’s Robinul Injection, 0.2mg/mL.
To lessen secretions and the side effects of some medications used during surgery, glycopyrrolate injection is utilized before during some procedures.
The debut of LYFE, a digital therapeutics solution, by Lupin Digital Health, a wholly owned company, was announced in January.
The debut of LYFE, a digital therapeutics solution, by Lupin Digital Health, a wholly owned company, was announced in January.
Shares of Lupin Ltd were trading at Rs 679 apiece, down 0.49 percent on BSE, at 10.37 AM on Friday.
